- Quicklinks for:
- CEU Home
- Current Students
- Recruiters
- Corporate Visitors
- Login
- Contact us
Round Table on Business Opportunities in Life Sciences
Date:
May 16, 2012 - 18:00 - 20:00
Building:
Frankel Leó út 30-34.
Room:
101
Event type:
Roundtable
Event audience:
Open to the Public
E-mail:
iei@ceubusiness.org 
We cordially invite you to participate in our next Round Table discussion on:
Business Opportunities and Innovations in Life Sciences
Biotech is a growing business sector."How can I get a slice of it?"
this event is co-organized by
the Institute for Entrepreneurship and Innovation at CEU Business School and our partner the Semmelweis Innovations at the Semmelweis University of Life Sciences.
The round table discussion will take place at the premises of the
CEU Business School on May 16, at 6 PM in Room 101.
Please find the description and invitation attached.
We very much hope, that you can attend this topical discussion.
Please be so kind to RSVP to iei@ceubusiness.org
.
.
.
Innovation in Life science is very different from innovation in other
fields because it involves the human body. Therefore, there is
virtually no room for margin of error, and regulatory regime for life
sciences also makes the innovation cycle quite different from other
sectors. Consequently, the commercialization of new innovation in life
science has been traditionally long and difficult. Even Pfizer faces
declining profit when there is no immediate successor to its cash cow
Lipitor. Nevertheless, life science is a growing business. How may
someone get a slice of it?
There have been some interesting new trends in this sector that also
have important implications for business models. For example, advances
in technology now allow doctors to perform operation at distance; with
certain devices patients can check their own health at home without
going through medical attendance. The popularity of smart phones and
social media also starts to play an increasing important role.
The subject of this Round Table is commercialization of new
technologies and innovation in life sciences. Hungary has been
traditionally very strong in this sector. Especially emphasized is
role of Hungary on world stage. Speakers include Peter Grossman, CEO
of Medicover, Zsombor Lacza, general manager at Semmelweis
Innovations, Attila Bérces, CEO of Omixon. Professor Paul Lacourbe
will moderate this Round Table.
fields because it involves the human body. Therefore, there is
virtually no room for margin of error, and regulatory regime for life
sciences also makes the innovation cycle quite different from other
sectors. Consequently, the commercialization of new innovation in life
science has been traditionally long and difficult. Even Pfizer faces
declining profit when there is no immediate successor to its cash cow
Lipitor. Nevertheless, life science is a growing business. How may
someone get a slice of it?
There have been some interesting new trends in this sector that also
have important implications for business models. For example, advances
in technology now allow doctors to perform operation at distance; with
certain devices patients can check their own health at home without
going through medical attendance. The popularity of smart phones and
social media also starts to play an increasing important role.
The subject of this Round Table is commercialization of new
technologies and innovation in life sciences. Hungary has been
traditionally very strong in this sector. Especially emphasized is
role of Hungary on world stage. Speakers include Peter Grossman, CEO
of Medicover, Zsombor Lacza, general manager at Semmelweis
Innovations, Attila Bérces, CEO of Omixon. Professor Paul Lacourbe
will moderate this Round Table.